Royalty Pharma plc vs Johnson & Johnson
RPRX vs JNJ — side-by-side comparison from reported financials. RPRX leads 4, JNJ leads 6 of 10 comparable metrics.
Royalty Pharma plc
RPRX · Healthcare
$56.93+1.28%Solid
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | RPRX | JNJ |
|---|---|---|
| Price | $56.93 | $261.79 |
| Market cap | $25.4B | $631B |
| Revenue (TTM) | $2.54B | $97.9B |
| Revenue growth | +2.1% | +5.6% |
| Net margin | 32.1% | 21.5% |
| Free cash flow | $2.98B | $22.2B |
| Net cash (debt) | ($7.93B) | ($27.8B) |
| 1-year price return | +57.5% | +37.0% |
| P/E | 40.2 | 29.9 |
| P/E vs own history (cheap-side %) | 53% | 16% |
| Dividend yield | 1.22% | 2.00% |
| Return on equity | 12% | 26% |
| Altman Z-score | 2.32 | — |
| CV checks passed | 10 of 11 | 10 of 11 |
| Employees | 100 | 140,800 |
Full résumé-style profiles: RPRX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.